✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Depo-Provera meningioma claims now turn on a harder question: how long were the shots?

Last reviewed: September 21, 2026

A lot of women remember the shorthand: "I was on Depo." That is a
start, but it usually is not enough for a serious meningioma claim
review.

The harder question is dates. When did the shots begin? Did they
continue for one year, four years, or longer? Was there a long gap?
Were the injections given at an OB/GYN office, a county health
clinic, a student clinic, or a primary-care practice that has since
changed names?

Those details matter more after the newer U.S. research on depot
medroxyprogesterone acetate, often shortened to DMPA. They also
matter because the federal Depo-Provera cases in MDL 3140 have moved
into a different stage. The litigation is still active in the
Northern District of Florida, and the JPML's September 2026 page
points readers to the current federal MDL reports. Public docket
trackers report more than 6,400 pending federal actions.

Our main Depo-Provera lawsuit
page explains
the broader allegation: women say long-term exposure to
Depo-Provera, Depo-SubQ Provera 104, or related DMPA shots is linked
to intracranial meningioma, and that warnings came too late. This
piece is narrower. It is about the record trail.

What changed with the U.S. study

The JAMA Neurology paper looked at a large U.S. health-data network.
The authors compared women who used depot medroxyprogesterone
acetate with matched comparison groups and reported a higher
relative risk of later meningioma diagnosis among DMPA users.
Neurology Today summarized the result as a relative risk of 2.43,
while also stressing something patients deserve to hear clearly: the
absolute risk is still low.

That is the tension in this litigation. The research does not mean
every person who used Depo-Provera is in danger. It does not prove
one woman's tumor came from one medicine. But it does make exposure
history harder to brush aside, especially when the history shows
years of injections.

The U.S. paper also gives lawyers and doctors a different kind of
support than the 2024 BMJ French study. The French study focused on
women who had surgery for intracranial meningioma and found
increased odds tied to prolonged injectable medroxyprogesterone
acetate use. The U.S. study used a U.S. database and looked at
diagnosis risk in a different way. Together, they are part of why
duration has become such a practical issue.

"Every three months" can become a messy paper chase

Depo-Provera is usually administered every three months. That sounds
easy to reconstruct until you try to do it ten or fifteen years
later.

One patient may have received shots at a health department clinic
before switching to a private OB/GYN. Another may have started after
childbirth, stopped for a while, then restarted through a different
provider. Someone else may remember the nurse visits but have no
pharmacy receipt because the clinic supplied the medication
directly.

So the first pass should be boring and methodical. Make a list of
every place that could have given the injection. Include old
addresses, maiden names, college clinics, county clinics, Planned
Parenthood locations, military or VA care, Medicaid plans, private
insurers, and any patient portals that might still exist. If a
clinic closed, ask where the records went. If the chart is gone, ask
for billing logs or medication administration records.

Do the same on the diagnosis side. A useful meningioma file usually
includes the first MRI or CT report, later imaging, neurology notes,
neurosurgery notes, radiation records if radiation was used, and
operative or pathology records if there was surgery. A note that
says "brain mass" is not the same as a confirmed intracranial
meningioma diagnosis.

The FDA label is part of the picture, not the whole picture

Pfizer's current Depo-Provera prescribing information lists a
December 2025 meningioma warning under recent major changes. The
warning section says to discontinue Depo-Provera CI if a meningioma
is diagnosed and to monitor patients for signs and symptoms of
meningioma.

That language is important, but it has limits. It is not a ruling
that Pfizer is liable. It is not proof that a particular tumor was
caused by DMPA. And it is not a reason to stop prescribed
contraception without talking to a clinician.

If you currently use Depo-Provera and have been told you have a
meningioma, bring the label and your injection history to your
doctor. The legal review can wait a few days. Medical decisions
should not be made from an internet article.

The court posture adds urgency without giving easy answers

Case Management Order No. 14 says the court understood that a
settlement program had been reached and that it would offer a
substantial percentage of pending MDL plaintiffs an opportunity to
resolve their claims. The same order says the registration deadline
for claimants to participate in that settlement program is November
30, 2026. It also sets procedures for cases that keep litigating
after the settlement program.

That does not answer every question for someone who has not filed.
It does not automatically include a new claimant. It does not
automatically exclude one either. Eligibility rules, state
deadlines, exposure proof, diagnosis proof, and the timing of legal
representation can all matter.

What it does tell us is that the paper trail should not wait. A case
review built on "I think I used it for a few years" is weaker than
one built on dated injection records, imaging reports, and treatment
notes.

A practical checklist

Start with these items:

injection dates for Depo-Provera, Depo-SubQ Provera 104, or other DMPA products;
provider names and clinic locations for each period of use;
pharmacy, insurance, Medicaid, or billing records if clinic charts are incomplete;
the first imaging report that identified the meningioma;
neurology, neurosurgery, radiation oncology, operative, and pathology records; and
notes showing symptoms, restrictions, repeat imaging, seizure care, vision issues, hearing issues, or work disruption.

Keep the file focused. A Depo-Provera review should center on DMPA
exposure, meningioma diagnosis, timing, treatment, and deadlines. If
your family is reviewing other prescription-drug injuries, Mass Tort
America keeps separate pages for Suboxone dental injury
claims and
Ozempic and GLP-1 injury
claims.

Short FAQ

Does the U.S. study prove my individual case?

No. It reports a population-level association. An individual claim
still depends on records, timing, diagnosis, alternative risk
factors, expert review, and state law.

Is every Depo-Provera user at high risk?

No. Neurology Today's summary of the JAMA Neurology study emphasized
that the relative risk was higher, but the absolute risk remained
low.

What if I cannot find every injection date?

That is common. Start with the providers most likely to have
administered the shots, then check insurance claim histories,
pharmacy benefit records, old portals, and billing records.

Should I stop Depo-Provera now?

Talk with your prescribing clinician. This article is not medical
advice, and stopping contraception without a plan can create other
risks.

Sources

Attorney Advertising. This article is for general information only.
It is not medical advice or legal advice. Reading it or submitting a
form does not create an attorney-client relationship. Every claim
depends on the person's records, exposure history, deadlines,
medical proof, and applicable law.

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →